Drug-induced fibrotic valvular heart disease

[1]  M. Galderisi,et al.  Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. , 2009, The Journal of clinical endocrinology and metabolism.

[2]  A. Rigby,et al.  Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. , 2008, European journal of endocrinology.

[3]  Jeroen J. Bax,et al.  Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[4]  C. Elangbam,et al.  5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[5]  C. Hamm,et al.  Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation. , 2008, International journal of cardiology.

[6]  L. Pierard,et al.  Cabergoline and the risk of valvular lesions in endocrine disease. , 2008, European journal of endocrinology.

[7]  R. Rothman,et al.  Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels , 2008, Journal of Pharmacology and Experimental Therapeutics.

[8]  V. G. Rasmussen,et al.  Heart valve disease associated with treatment with ergot‐derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson’s disease , 2007, Journal of internal medicine.

[9]  P. Franken,et al.  Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. , 2007, The American journal of cardiology.

[10]  A. Bossuyt,et al.  In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. , 2007, European heart journal.

[11]  W. Poewe,et al.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.

[12]  Anthony H V Schapira,et al.  Treatment options in the modern management of Parkinson disease. , 2007, Archives of neurology.

[13]  R. E. Togrol,et al.  DOPAMINE AGONISTS AND CARDIAC VALVULOPATHY IN PARKINSON DISEASE: A CASE-CONTROL STUDY , 2007, Neurology.

[14]  H. Reichmann,et al.  Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[15]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[16]  A. Antonini,et al.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.

[17]  W. Haverkamp,et al.  Dopamine agonists and the risk of cardiac-valve regurgitation. , 2007, The New England journal of medicine.

[18]  E. Wolf,et al.  Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[19]  E. Chung,et al.  Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists , 2006, Movement disorders : official journal of the Movement Disorder Society.

[20]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[21]  Robert J Levy,et al.  Serotonin transporter mechanisms and cardiac disease. , 2005, Circulation.

[22]  M. Hamon,et al.  Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice , 2005, Circulation.

[23]  P. Marcos-Alberca,et al.  Cabergoline-related severe restrictive mitral regurgitation. , 2005, The New England journal of medicine.

[24]  G. Mazzotti,et al.  Trends in ecstasy use in the United States from 1995 to 2001: comparison with marijuana users and association with other drug use. , 2005, Experimental and clinical psychopharmacology.

[25]  M. Heckman,et al.  Valvular heart disease in patients taking pergolide. , 2005, Mayo Clinic proceedings.

[26]  R. Fossmark,et al.  Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.

[27]  P. O'Suilleabhain,et al.  Pergolide use in Parkinson disease is associated with cardiac valve regurgitation , 2004, Neurology.

[28]  A. Lang,et al.  Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists , 2004, Movement disorders : official journal of the Movement Disorder Society.

[29]  O. Rascol,et al.  New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance , 2004, Movement disorders : official journal of the Movement Disorder Society.

[30]  Patrick Santens,et al.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease , 2004, The Lancet.

[31]  N. Hattori.  Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease , 2003, Current opinion in neurology.

[32]  A. Flamez,et al.  Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide , 2003, Neurology.

[33]  A. Kerr,et al.  Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. , 2003, Journal of the American College of Cardiology.

[34]  V. Setola,et al.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.

[35]  D. el Allaf,et al.  [Clinical case of the month. Triple valvular dysfunction associated with long-term ergotamine therapy]. , 2003, Revue medicale de Liege.

[36]  R. Levy,et al.  Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. , 2002, The American journal of pathology.

[37]  M. Millan,et al.  Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[38]  F. Viallet,et al.  Fibrotic valvular heart disease subsequent to bromocriptine treatment. , 2002, Cardiology in review.

[39]  V. Rigolin,et al.  Appetite suppressants and valvular heart disease. , 2002, Current opinion in cardiology.

[40]  R. Doblin.  A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA , 2002, Journal of psychoactive drugs.

[41]  J. Panza,et al.  Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. , 2001, JAMA.

[42]  K. Anstrom,et al.  The Progression of Fenfluramine-Associated Valvular Heart Disease Assessed by Echocardiography , 2001, Annals of Internal Medicine.

[43]  Lippincott Williams Wilkins,et al.  Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001, Neurology.

[44]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[45]  T. Naqvi,et al.  Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. , 2000, The American journal of cardiology.

[46]  T. Ryan,et al.  Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. , 2000, Circulation.

[47]  J. Gardin,et al.  Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. , 2000, JAMA.

[48]  R. Rothman,et al.  Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. , 2000, The American journal of cardiology.

[49]  I.A. Jagroop, D.P. Mikhailidis.  An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models , 2000, Platelets.

[50]  T. Mulderink,et al.  Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. , 1999, The American journal of cardiology.

[51]  T. Najarian,et al.  Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. , 1999, Circulation.

[52]  A. Burger,et al.  Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. , 1999, Journal of the American College of Cardiology.

[53]  C. Raftopoulos,et al.  Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. , 1999, The Journal of clinical endocrinology and metabolism.

[54]  Jagmeet P. Singh,et al.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.

[55]  A. Fishman.  Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[56]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[57]  J. Vessey,et al.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.

[58]  N. Weissman,et al.  An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.

[59]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[60]  B. Maisch,et al.  Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. , 1997, European heart journal.

[61]  J. Van Dorpe,et al.  Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. , 1996, The Journal of heart valve disease.

[62]  J. Webster,et al.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.

[63]  R. Pakala,et al.  Mitogenic effect of serotonin on vascular endothelial cells. , 1994, Circulation.

[64]  A. Tajik,et al.  Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations , 1992, Annals of Internal Medicine.

[65]  E. C. Stein,et al.  Long‐term weight control study II (weeks 34 to 104) , 1992, Clinical pharmacology and therapeutics.

[66]  C. Cox,et al.  Long‐term Weight Control Study VI , 1992 .

[67]  J. Pouysségur,et al.  Serotonin stimulates DNA synthesis in fibroblasts acting through 5–HT1B receptors coupled to a Gi-protein , 1988, Nature.

[68]  M. Moskowitz,et al.  Stimulation of aortic smooth muscle cell mitogenesis by serotonin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Y. Mizuno,et al.  Pergolide in the treatment of Parkinson's disease , 1984, Neurology.

[70]  A. Mushlin,et al.  A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. , 1984, Archives of internal medicine.

[71]  P. Lecompte,et al.  Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. , 1974, American heart journal.

[72]  K. A. Misch.  Development of heart valve lesions during methysergide therapy. , 1974, British medical journal.

[73]  J. Graham.  CARDIAC AND PULMONARY FIBROSIS DURING METHYSERGIDE THERAPY FOR HEADACHE , 1967, The American journal of the medical sciences.

[74]  F. Galland,et al.  [Clinical case of the month]. , 1966, Archivos del Instituto de Cardiologia de Mexico.

[75]  P. A. Wallenborn,et al.  Agammaglobulinemia , 1960 .

[76]  K. Serri,et al.  Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas , 2008, Pituitary.

[77]  E. M. Quintana,et al.  Valvulopatía por uso de ergotamina , 2005 .

[78]  Francisco Jiménez Cabrera,et al.  [Valvular heart disease associated with ergotamine]. , 2005, Revista espanola de cardiologia.

[79]  M. Worsham,et al.  Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[80]  W F Stewart,et al.  Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. , 1992, JAMA.

[81]  A. J. Hauck,et al.  Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. , 1990, Archives of pathology & laboratory medicine.

[82]  J. Seward,et al.  Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. , 1990, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[83]  H. Jenzer,et al.  [Disease course of ergotism with femoral artery occlusion and mitral insufficiency]. , 1973, VASA. Zeitschrift fur Gefasskrankheiten.